APA (7th ed.) Citation

P, P., O, I., D, M., S, B., M, K., J, L., . . . P, S. (2026). Safety of biologics and Janus kinase inhibitors in inflammatory bowel disease patients with low cardiovascular risk. Crohn's & colitis 360, 8(2), otag039. https://doi.org/10.1093/crocol/otag039

Chicago Style (17th ed.) Citation

P, Patel, et al. "Safety of Biologics and Janus Kinase Inhibitors in Inflammatory Bowel Disease Patients with Low Cardiovascular Risk." Crohn's & Colitis 360 8, no. 2 (2026): otag039. https://doi.org/10.1093/crocol/otag039.

MLA (9th ed.) Citation

P, Patel, et al. "Safety of Biologics and Janus Kinase Inhibitors in Inflammatory Bowel Disease Patients with Low Cardiovascular Risk." Crohn's & Colitis 360, vol. 8, no. 2, 2026, p. otag039, https://doi.org/10.1093/crocol/otag039.